Merck Sharpe and Dohme welcomes NICE backing for hepatitis therapy

Merck Sharpe and Dohme has responded positively to a new National Institute for Health and Clinical Excellence (NICE) recommendation for a hepatitis C treatment option.

The authority has issues a final appraisal determination recommending combination therapy with peginterferon alfa and ribavirin for hepatitis C patients co-infected with HIV, or for those who require re-treatment.

This recommendation encompasses Merck Sharpe and Dohme's ViraferonPeg and Rebetol treatment regimen and follows on from previous guidance recommending the therapy for moderate-severe chronic hepatitis C and mild chronic hepatitis C sufferers.

Dr Harpal Lamba of Merck Sharpe and Dohme Medical Affairs said: "This guidance will support healthcare professionals to consistently manage patients with hepatitis C when re-treatment is needed or where patients are co-infected with HIV."

It is estimated that between 200,000 to 500,000 people are infected with hepatitis C in England and Wales.

Earlier this month, Merck Sharpe and Dohme highlighted new clinical research into its hepatitis C treatment boceprevir, demonstrating the potential benefits of the developmental therapy.